Abstract
Chronic renal failure (CRF) is a major public health problem worldwide. Patients living with CRF are considered to follow a chronic inflammatory state due to multiple factors. From a dermatologic point of view, there is a high frequency of dermatoses associated with this condition. They can be divided into specific and nonspecific, the latter having the highest prevalence, but all of them show a significant impact on the quality of life of affected patients. Xerosis, bruising, and itching are ubiquitous in this population and are considered multifactorial. Among them, xerosis, pale skin and itching are the most prevalent ones. On the other hand, specific dermatoses are classified as acquired perforating disorders, bullous dermatoses, calcification disorders, nephrogenic systemic fibrosis, specific nail changes, and uremic frost. Most skin disorders are benign and do not affect the course of CRF. On several occasions skin disorders can predict the initiation of a renal replacement plan, or may be precipitated by it.
Keywords
References
Registro Uruguayo de Diálisis. www.nefrouruguay.com.
Barco D, Giménez-Arnau A. Xerosis: a dysfunction of the epidermal barrier. Actas Dermosifilogr. 2008;99:671–82.
Lupi O, Rezende L, Zangrando M, Sessim M, Silveira CB, Sepulcri MAS, et al. Manifestacões cutáneas na doenca renal terminal. An Bras Dermatol. 2011;86(2):319–26.
Falodun O, Ogunbiyi A, Salako B, George AK. Skin changes in patients with chronic renal failure. Saudi J Kidney Dis Transpl [serial online]. 2011. Cited 16 Mar 2015.;22:268–72.
Udayakumar P, Balasubramanian S, Ramalingam KS, Lakshmi C, Srinivas CR, Mathew AC. Cutaneous manifestations in patients with chronic renal failure on hemodialysis. Indian J Dermatol Venereol Leprol. 2006;72(2):119–25.
Leena JA, Noman MU, Islam MMSU, Ahmed AS, Ahmed DS, Rahma MM. Cutaneous manifestations of chronic kidney disease – an observational study in 100 cases. Faridpur Med Coll J. 2012;7:33–6.
Brewster UC. Dermatologic disease in patients with CKD. Am J Kidney Dis. 2008;51(2):331–44.
Kidney International Supplements. 2013;3:136–50. doi:https://doi.org/10.1038/kisup.2012.72.
Kuypers D. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5(3):157–70.
Thomas EA, Pawar B, Thomas A. A prospective study of cutaneous abnormalities in patients with chronic kidney disease. Indian J Nephrol. 2012;22:116–20.
Batista Peres LA, Passarini SR, Ferreira de Barros Tocollini Branco M, Kruger LA. Skin lesions in chronic renal dialysis. J Bras Nefrol. 2014;36(1):1–6.
Attia EAS, Hassan SI, Youseef NM. Cutaneous disorders in uremic patients on hemodialysis: an Egyptian case-controlled study. Inter J Dermatol. 2010;49:1024–30.
Robinson-Bostom L, DiGiovanna JJ. Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol. 2000;43(6):987–90.
Cordova KB, Oberg TJ, Malik M, Robinson-Bostom L. Dermatologic conditions seen in end-stage renal disease. Semin Dial. 2009;22(1):45–55.
Avermaete A, Altmeyer P, Bacharach-Buhles M. Skin changes in dyalisis patients: a review. Nephrol Dial Transplant. 2001;16:2293–6.
Fett N, Haynes A, Joy Propert KJ, Margolis DJ. Predictors of malignancy development in patients with chronic pruritus. J Dermatol Sci. 2016;82(2):123–8.
Wang A, Elshehadeh R, Rao D, Yap E. Roles of aldosterone receptor antagonists in heart failures, hypertension, and chronic kidney disease. J Nurse Pract. 2016;12(3):201–6.
Chao CT, Lai CF, Huang JW. Risk factors for herpes zoster reactivation in maintenance hemodialysis patients. Eur J Intern Med. 2012;23:711–5.
Mazen S, Kurban AB, Kibbi A-G. Cutaneous manifestations of chronic kidney disease. Clin Dermatol. 2008;26:255–64.
Belloni Fortina A, Piaserico S, Alaibac M. 2009. Squamous cell carcinoma. In: The SCOPE Collaborative Group, editor. Skin cancer after organ transplantation. Cancer treatment and research 146. Rosen T, Series Editor. Springer, p. 241–61.
Chaturvedy M. Dermatologic problems in CKD; ocular manifestations in CKD. Clin Nephrol. 2012;1(4):284–90.
Charkhchian M, Beheshti A, Zangivand AA. Nail disorder among patients on maintenance hemodialysis. Dermatol Sin. 2003;31(1):7–10.
Saray Y, Seckin D, Gulec AT, Akgun S. Nail disorders in hemodialysis patients and transplant recipients: a case-control study. J Am Acad Dermatol. 2004;50(2):197–202.
Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol. 2001;44(1):100–8.
Daudén Tello E, Ruiz Genao D, Fraga FJ. Calcificación vascular cutánea. Correlación clínicopatológica y proposición de una nueva clasificación de las calcinosis. Actas Dermosifiliogr. 2002;93(1):23–34.
Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol. 2012;26(4):489–503.
Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563–72.
Jimenez SA, Arlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, et al. Dialysis-associated systemic fibrosis. Study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum. 2004;50:2660–6.
Shavit L, Grenader T, Lifschitz M, Slotki I. Use of pregabalin in the management of chronic uremic pruritus. J Pain Symptom Manage. 2013;45(4):776–81.
Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006;69:1626–32.
Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis. 2015;65(5):763–72.
Ramsey HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cáncer in renal transplant recipients. Am J Kidney Dis. 2000;36(1):167–76.
Athar M, Walsh SB, Kopelvich L, Elmets CA. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients. Arch Biochem Biophys. 2011;508(2):159–63.
Keczkes K, Farr M. Bullous dermatosis of chronic renal failure. Br J Dermatol. 1976;95(5):541–6.
Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care. 2008;35(2):251–vi.
Mohan D, Railey M. Uremic frost. Kidney Int. 2012;81:1153.
Szepietowski JC, Reich A, Schwatrz RA. Uraemic xerosis. Nephrol Dial Transplant. 2004;19(11):2709–12.
Winhoven S. Nodular prurigo – a retrospective analysis. Br J Dermatol. 1985;113:431–9.
Carrascosa JM, Ferrándiz C. Estrategias terapéuticas en el prurigo nodular. Piel. 2001;16(7):360–4.
Glynne P, Deacon A, Goldsmith D, Pusey C, Clutterbuck E. Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria? Am J Kidney Dis. 1999;34(1):155–60.
Zettersten EM, Ghadially R, Feingold KR, Crumrine D, Elias PM. Optimal ratios of topical stratum corneum lipids improve barrier recovery in chronologically aged skin. J Am Acad Dermatol. 1997;37(3 Pt 1):403–8.
Weisshaar E, Dunker N, Gollnick H. Capsaicin therapy in humans with hemodialysis-related pruritus. Neurosci Lett. 2003;345(3):192–4.
Molinar VE, Taylor SC, Pandya AG. What’s new in objective assessment and treatment facial hyperpigmentation? Dermatol Clin. 2014;32:123–35.
Sarkar R, Arora P, Grag KV. Cosmeceuticals for hyperpigmentation: what is available? J Cutan Aesthet Surg. 2013;6(1):4–11.
Arora P, Sarkar R, Grag VK, Arya L. Lasers for treatment of melasma and post-inflammatory hyperpigmentation. J Cutan Aesthet Surg. 2012;5(2):93–103.
Omi T, Yamashita R, Kawana S, Sato S, Naito Z. Low fluence Q-switched Nd: YAG laser toning and Q-switched ruby laser in the treatment of melasma: a comparative split-face ultrastructural study. Laser Ther. 2012;21(1):15–21.
Guerrero D. Dermocosmetic management of hyperpigmentations. Ann Dermatol Venereol. 2012;139(Suppl 3:S1):S115–8.
González-Lara L, Gómez-Bernal S, Vázquez-López F, VivancoAllende B. Acquired perforating dermatosis: a report of 8 cases. Actas Dermosifilogr. 2014;105(6):e-39–43.
Farrell A. Acquired perforating dermatosis in renal and diabetic patients. 1997;9056(349):895–96.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Glossary
- Dyschromia
-
Alteration of the color of the skin.
- Gynecomastia
-
Enlargement of the breast in the males, caused by an excess of estrogens.
- Macroglossia
-
Excessively large tongue.
- Microangiopathy
-
Pathologic processes of the microvessels.
- Pruritogenic substances
-
Substances capable of causing pruritus (itching).
- Raynaud’s phenomenon
-
Abrupt onset of digital paleness followed by cyanosis and erythema in response to cold.
- Teratogenic effect
-
Capacity of some substances of generate physical defects in the developing embryo.
- Uroporphyrins
-
Porphyrins produced by oxidation of uroporphyrinogen, which can be excreted in excess in the urine in the context of porphyrias.
- Xerostomia
-
Decreased salivary flow (dry mouth).
Rights and permissions
Copyright information
© 2018 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Varela, L.D., Borges, A.L., Centanni, A.N. (2018). Dermatologic Manifestations in Renal Failure. In: Bonamigo, R., Dornelles, S. (eds) Dermatology in Public Health Environments. Springer, Cham. https://doi.org/10.1007/978-3-319-33919-1_44
Download citation
DOI: https://doi.org/10.1007/978-3-319-33919-1_44
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33917-7
Online ISBN: 978-3-319-33919-1
eBook Packages: MedicineMedicine (R0)